Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

eived a median of 22 months of treatment.

Hemolysis was significantly reduced with eculizumab treatment in patients with all levels of baseline hemolysis. In patients with the lowest quartile of hemolysis (< 1490 U/L), LDH was reduced from 1077 +/- 42 U/L pre-eculizumab to 323 +/- 22 U/L during the first six months and to 347 +/- 47 U/L during the most recent six months of Soliris therapy (P<0.001 for each comparison to baseline). Hemolysis was also significantly reduced during both the first and most recent six months of Soliris therapy in patients with mild anemia (Hgb of greater than or equal to 10.5 g/L) and minimal transfusion support prior to treatment (0 or 1 transfusion episode in the previous year) (P<0.001 for all subgroups at both time intervals).

In the study, patients who might have been considered to have less severe disease were found to have an elevated risk of blood clots prior to therapy and experienced the following reductions in the incidence of blood clots during Soliris therapy: for patients with the lowest quartile of baseline hemolysis, the rate decreased from 10.8 to 4.5 events per 100 patient years (P=0.009, n=48), for those with mild anemia from 5.2 to 0.8 events per 100 patient years (P<0.001, n=55), and for those with minimal pretreatment transfusion support from 4.9 to 0.0 events per 100 patient years (P=0.063, n=22).

Soliris treatment was associated with significant improvements in fatigue (as measured by the FACIT-Fatigue instrument), regardless of the baseline level of hemolysis, anemia, or pretreatment transfusion requirements. At baseline, patients who had the lowest levels of hemolysis, mild anemia, or minimal transfusion requirements reported fatigue. With patients in the lowest quartile of baseline hemolysis, FACIT-Fatigue scores improved by 6 points during the first six months and by 8 points during the most recent six months of Soliris therapy (P<0.001 for each comparison to baseline); an increase of 3 or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 3, 2014  Edison Pharmaceuticals today ... placebo-controlled trial in pediatric patients. Rett syndrome patients ... in head circumference.  Decreased brain growth and head ... Rett syndrome is a genetic neurodevelopmental disorder ... 24 months of age. It is characterized by ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... Reportbuyer.com has added a new market ... for Services and Devices https://www.reportbuyer.com/product/1923024/Bariatric-Surgery-Global-Markets-for-Services-and-Devices.html ... or weight loss surgery is a generic term ... deal with the surgical treatment of obesity. These ... performed in both open and laparoscopic types. Bariatric ...
Breaking Medicine Technology:Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 2Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 3Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25Bariatric Surgery: Global Markets for Services and Devices 2Bariatric Surgery: Global Markets for Services and Devices 3Bariatric Surgery: Global Markets for Services and Devices 4Bariatric Surgery: Global Markets for Services and Devices 5Bariatric Surgery: Global Markets for Services and Devices 6Bariatric Surgery: Global Markets for Services and Devices 7Bariatric Surgery: Global Markets for Services and Devices 8Bariatric Surgery: Global Markets for Services and Devices 9Bariatric Surgery: Global Markets for Services and Devices 10
... , NEW YORK , Aug. 2 ... medical membership, announced today that, effective August 1, 2010 ... Indemnity Reference Laboratory Networks.  This expansion ensures broader choices for ... on service, quality and choice, and reduces the need for ...
... FRANKLIN LAKES, N.J. , Aug. 2 BD ... global medical technology company, today announced the completion of the sale of its ... blades product platform to one of RoundTable,s portfolio companies, Aspen Surgical Products, Inc. ... On June ...
Cached Medicine Technology:Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers 2BD Completes Sales of Ophthalmic Systems Unit and Surgical Blades Product Platform 2
(Date:9/2/2014)... 2014 Autumn is well under ... celebrate the new season with worldwide people. Recently, ... announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and ... 2014. , Since 2002 HostGator has been ... the company’s reputation for reliability remains with it ...
(Date:9/2/2014)... Norway are associated with higher infant mortality. The findings ... a journal of the Nordic Federation of Societies of ... given birth at least once before (multiparous) and those ... unplanned deliveries, which may increase the risk of death ... babies were born in Norway according to the Statistics ...
(Date:9/2/2014)... include the sensation of grit in the eye, frequently ... are poorly understood., The researchers base their findings on ... 57) from the TwinsUK cohort, drawn from the registry ... is widely regarded as representative of the UK general ... wide range of diseases and genetic traits over the ...
(Date:9/2/2014)... concentrated pot might be risky business for women, ... The study is the first to demonstrate sex ... , Psychology professor Rebecca Craft showed that, ... at least 30 percent more sensitive than males ... ingredient in cannabis. Females also develop tolerance to ...
(Date:9/2/2014)... Tampa, Fla. (PRWEB) September 02, 2014 ... will join together in Tampa Bay from September ... sixth annual Scientific Symposium and FARA Energy Ball ... the USF Ataxia Research Center in their pursuit ... worldwide affected by the progressive neuromuscular disease Friedreich’s ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Unplanned births out-of-hospital increases risk of infant mortality 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 3
... Award Winning Artist Describe Why They ... May 29 Susan G. Komen for the Cure(R),s ... African-American,leaders -- each with different backgrounds and personal stories ... around the globe to help,end breast cancer forever. The ...
... 29 Kewaunee Scientific,Corporation (Nasdaq: KEQU ) ... Company,s quarterly cash dividend to eight cents per,outstanding ... in the previous,quarter, payable on June 23, 2008 ... on June 9, 2008., Kewaunee Scientific Corporation ...
... 29 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... Meeting of Stockholders Thursday, June 12, 2008 at ... Pickering Hale & Dorr, 60 State,Street, Boston, MA., ... Alseres Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc. (ALSE) ...
... to Donate One Dollar to Change Lives, CHICAGO, ... a Bite out of Hunger" during its 70th Annual,Donut ... hundreds of Donut,taggers will hit the streets during a ... World War I when volunteers handed out donuts,to troops ...
... and Purdue universities Thursday announced the creation of ... a medical research initiative that will combine the ... swiftly transform discoveries into better patient care and ... has awarded a five-year Clinical and Translational Science ...
... Cancer Center researchers have identified that a combination of ... leukemia cells previously resistant to conventional forms of therapy. ... of the bone marrow caused by a specific genetic ... of leukemia. Imatinib mesylate, or Gleevec, is a highly ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 3Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 4Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:The Salvation Army Takes a Bite Out of Hunger 2Health News:Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: